ArticleNature metabolism2023
The glucose transporter 2 regulates CD8
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 52 citations in OpenAlex.
- Solute Carrier transporters in tumor metabolism and immune modulation: implications for therapy.Journal of translational medicine · 2026Review
- Insulin Resistance and Inflammation.International journal of molecular sciences · 2026Review
- Glycolytic reprogramming in cancer: immune crosstalk, nutrient competition, and supportive care perspectives.Frontiers in immunology · 2026Review
- The High-Altitude Adaptation Characteristics of Microbiota-Host Cross-Talk in Yak Gastrointestinal Track.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Loss ofLife science alliance · 2026Article
- GLUT1 and GLUT3 in brain glucose metabolism: mechanisms, regulation, and implications for metabolic disorders.Metabolic brain disease · 2025Review
- Resolution Pharmacology: State-of-the-art and therapeutic landscape.Pharmacological reviews · 2025Review
- Metabolites as agents and targets for cancer immunotherapy.Nature reviews. Drug discovery · 2025Review
- USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Glucose-dependent glycosphingolipid biosynthesis fuels CD8Cell metabolism · 2025Article
- Multiple low dose streptozotocin-induced diabetes as a model for studying autoimmune diabetes in humans.Animal models and experimental medicine · 2025Review
- Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies.Experimental hematology & oncology · 2025Review
- Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment.Journal of translational medicine · 2025Review
- Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Dysregulated mast cell activation induced by diabetic milieu exacerbates the progression of diabetic peripheral neuropathy in mice.Nature communications · 2025Article
- Targeting CD38 immunometabolic checkpoint improves metabolic fitness and cognition in a mouse model of Alzheimer's disease.Nature communications · 2025Article
- Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer.Nature reviews. Drug discovery · 2025Review
- Autophagy regulator ATG5 preserves cerebellar function by safeguarding its glycolytic activity.Nature metabolism · 2025Article
- RNA-binding proteins as versatile metabolic regulators.npj metabolic health and disease · 2025Article
- The impact of metabolic reprogramming in hepatocellular carcinoma on T cell.Frontiers in immunology · 2025Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
28 authors at 7 institutions in 4 countries.
Hongmei Fu *William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Juho Vuononvirta *William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Silvia FantiWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Fabrizia BonacinaDepartment of Pharmacological and Biomolecular Sciences (DisFeB), Università Degli Studi di Milano, Milan, Italy.ORCID 0000-0002-2611-1177
Antonio D'AmatiSection of Anatomical Pathology Department of Precision and Regenerative Medicine, University of Bari Medical School, Bari, Italy.ORCID 0000-0002-4810-1201
Guosu WangWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Thanushiyan PoobalasingamWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Maria FankhaenelBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-1218-3820
Davide LucchesiWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-8019-556X
Rachel ColebyWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
David TarussioFaculty of Biology and Medicine, Center for Integrative Genomics, Génopode Building - UNIL Sorge, University of Lausanne, Lausanne, Switzerland.
Bernard ThorensFaculty of Biology and Medicine, Center for Integrative Genomics, Génopode Building - UNIL Sorge, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3738-0129
Robert J HearndenBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-6721-6207
M Paula LonghiWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Paul GrevittBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-8224-1315
Madeeha H SheikhWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Egle SolitoWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0001-5279-0049
Susana A GodinhoBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-0638-065X
Michele BombardieriWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
David M SmithDiscovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, UK.ORCID 0000-0001-6831-280X
Dianne CooperWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0002-5553-9447
Asif J IqbalInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-3224-3651
Jeffrey C RathmellDepartment of Pathology, Microbiology, and Immunology, Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-4106-3396
Samuel SchaeferDepartment of Pathology, Microbiology, and Immunology, Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Valle MoralesBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-0856-5121
Katiuscia BianchiBart's Cancer Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Giuseppe Danilo NorataDepartment of Pharmacological and Biomolecular Sciences (DisFeB), Università Degli Studi di Milano, Milan, Italy.ORCID 0000-0002-6081-1257
Federica M Marelli-BergWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. f.marelli-berg@qmul.ac.uk.ORCID 0000-0001-8747-5823
Queen Mary University of London · GBUniversity of Lausanne · CHUniversity of Milan · ITVanderbilt University Medical Center · USAstraZeneca (United Kingdom) · GBUniversity of Bari Aldo Moro · ITUniversity of Birmingham · GB
Funding
Exploiting metabolic vulnerabilities of CD4 T cell subsets to control inflammatory diseaseR01DK105550 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2015 to 2026
$4.7MMetabolic Barriers to T Cell Activation in Clear Cell Renal Cell CarcinomaR01CA217987 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey C Rathmell · 2018 to 2026
$4.3MNCI NIH HHS R01 CA217987NIDDK NIH HHS R01 DK105550
Abstract
T cell activation is associated with a profound and rapid metabolic response to meet increased energy demands for cell division, differentiation and development of effector function. Glucose uptake and engagement of the glycolytic pathway are major checkpoints for this event. Here we show that the low-affinity, concentration-dependent glucose transporter 2 (Glut2) regulates the development of CD8
Indexed as
GlucoseGlucose Transport Proteins, FacilitativeAnimalsBiological TransportCD8-Positive T-LymphocytesCell DifferentiationHumansMiceGlucoseGlucose Transport Proteins, Facilitative
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.